trial

D-serine and Cognitive Remediation in Schizophrenia

NCTId NCT02156908
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 8 (actual)
Sponsored by Nathan Kline Institute for Psychiatric Research
Primary completion 2015-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
8 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2014-08
Primary completion
2015-12
Eligibility
ALL · 18 Years · 64 Years

Interventions & indications

Drugs
D-serine

Sponsors

Nathan Kline Institute for Psychiatric ResearchLead Sponsor

Investigators

1
Joshua T Kantrowitz, MDPrincipal Investigator

Sites

1 total
Orangeburg, United States

Linked catalysts

1
D-serine and Cognitive Remediation in Schizophrenia — primary completion2015-12

Facts & assertions

4 sourced
Enrollment
8
Phase
PHASE2
Primary Completion Date
2015-12
Status
COMPLETED
relationships
The graph out of here
drug
D-serine
drug
lead_sponsor
Nathan Kline Institute for Psychiatric Research
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Joshua T Kantrowitz, MD
person